3-氯-5-苯基-1,2-恶唑 | 31329-61-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 3-氯-5-苯基-1,2-恶唑
• 英文名称: 3-chloro-5-phenylisoxazole
• 英文别名: 3-chloro-5-phenyl-isoxazole；5-phenyl-3-chloroisoxazole；3-Chlor-5-phenyl-isoxazolin；3-Chlor-5-phenyl-isoxazol；3-Chlor-5-Phenylisoxazol；3-chloro-5-phenyl-1,2-oxazole
• CAS: 31329-61-0
• 化学式: C₉H₆ClNO
• mdl: MFCD06407629
• 分子量: 179.606
• InChiKey: KXRGBILEIVWKAL-UHFFFAOYSA-N

物化性质

• 熔点：
  36-37 °C
• 沸点：
  100-102 °C(Press: 1 Torr)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-5-苯基-1,2-恶唑 在 硝酸 作用下， 生成 3-chloro-5-(4-nitrophenyl)isoxazole
  参考文献：
  名称：

  Isoxazole anthelmintics

  摘要：

  A series of 3-halo-5-phenyl- and 3-phenyl-5-haloisoxazoles has demonstrated anthelmintic activity at doses ranging from 16 to 500 mg/kg orally against the rat roundworm, Nippostrongylus braziliensis. In the 5-phenyl series a halogen at the 3 position of the isoxazole ring was required for activity. However, in the 3-phenyl series activity was maintained after replacement of the 5-halogen with certain alkoxyl, thioalkoxyl, or amino groups. The 3-phenyl and 5-phenyl series apparently are not acting biologically at a common receptor site. Synthetic methods and structure-activity relationships are discussed.

  DOI：

  10.1021/jm00217a014
• 作为产物：
  描述：

  苯乙炔 在 ammonium hydroxide 、 盐酸羟胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 3-氯-5-苯基-1,2-恶唑
  参考文献：
  名称：

  Tandem Synthesis of 3-Halo-5-Substituted Isoxazoles from 1-Copper(I) Alkynes and Dihaloformaldoximes

  摘要：

  A tandem synthesis of 3-halo-5-substituted isoxazoles has been developed from 1-copper(I) alkynes and dihaloformaldoximes under base-free conditions. Thus, 1,3-dipolar cycloaddition and all its drawbacks can now be avoided completely.

  DOI：

  10.1021/ol503008t

文献信息

• Isoxazole compounds useful for the prophylaxis or treatment of nervous
  申请人：Sankyo Company, Limited

  公开号：US06005116A1

  公开（公告）日：1999-12-21

  Isoxazole compounds having the following general formula: ##STR1## wherein R.sup.1 represents an optionally substituted aryl group or aromatic heterocyclic group; R.sup.2 represents a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an alkoxy group, a cyano group, a carboxyl group, an alkanoyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group; R.sup.3 represents an optionally substituted amino group or a saturated heterocyclic group; X represents an oxygen atom or a sulfur atom; and n is an integer of from 2 to 6. These compounds have excellent monoamine oxidase inhibitory activity and are useful as a therapeutic agent or a preventive agent against nervous diseases such as depression.

  异噁唑化合物具有以下一般式：##STR1##其中R.sup.1代表可选择取代的芳基或芳香杂环基；R.sup.2代表氢原子、卤素原子、可选择取代的烷基、烯基、炔基、环烷基、环烯基、烷氧基、氰基、羧基、烷酰基、烷氧羰基或可选择取代的氨基甲酰基；R.sup.3代表可选择取代的氨基或饱和杂环基；X代表氧原子或硫原子；n为2到6的整数。这些化合物具有优异的单胺氧化酶抑制活性，并可用作治疗剂或预防剂，用于抑郁等神经疾病。
• Thrombin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06544982B1

  公开（公告）日：2003-04-08

  A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

  一种具有以下公式的凝血酶受体拮抗剂，用于抑制血小板聚集。这些化合物可用于作用于凝血酶受体的方法，包括向哺乳动物，最好是人类，投与治疗有效但非毒性量的该化合物。
• Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives, their preparation and their therapeutic use
  申请人：Sankyo Company Limited

  公开号：EP0456519A1

  公开（公告）日：1991-11-13

  Compounds of formula (l) : [in which : R1 is hydrogen, halogen or alkyl ; R2 is hydrogen, alkyl, optionally substituted phenyl or a heterocycle; or R1 and R2 together form a group of formula -CR4=CR5-CR6=CR7-, where R4, R5, R6 and R7 are hydrogen, halogen, alkyl group, alkoxy, halomethyl, alkylamino, dialkylamino, hydroxy, nitro, aliphatic carboxylic acylamino or amino ; and R3 is piperidyl, substituted piperidyl or quinuclidinyl] are useful in the treatment and prophylaxis of cognitive disorders, notably senile dementia, including Alzheimer's disease. Processes for preparing the compounds are also provided.

  式(l)化合物： [其中 ：R1 是氢、卤素或烷基；R2 是氢、烷基、任选取代的苯基或杂环；或 R1 和 R2 一起形成式 -CR4=CR5-CR6=CR7- 的基团，其中 R4、R5、R6 和 R7 是氢、卤素、烷基、烷氧基、卤代甲基、烷基氨基、二烷基氨基、羟基、硝基、脂肪族羧酰基氨基或氨基；和 R3 是哌啶基、取代的哌啶基或奎宁基]可用于治疗和预防认知障碍，特别是老年痴呆症，包括阿尔茨海默氏症。此外，还提供了制备这些化合物的工艺。
• ISOXAZOLE DERIVATIVES
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0885891A1

  公开（公告）日：1998-12-23

  The isoxazole derivatives having the following general formula: [wherein R1 represents an optionally substituted aryl group or aromatic heterocyclic group; R2 represents a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an alkoxy group, a cyano group, a carboxyl group, an alkanoyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group; R3 represents an optionally substituted amino group or a saturated heterocyclic group; X represents an oxygen atom or a sulfur atom; n is an integer of from 2 to 6] has an excellent monoamine oxidase inhibitory activity, and is useful as a therapeutic agent or a preventive agent against nervous diseases such as depression.

  具有以下通式的异噁唑衍生物： [其中 R1 代表任选取代的芳基或芳香杂环基团；R2 代表氢原子、卤素原子、任选取代的烷基、烯基、炔基、环烷基、环烯基、烷氧基、氰基、羧基、烷酰基、烷氧羰基或任选取代的氨基甲酰基；R3 代表任选取代的氨基或饱和杂环基团；X 代表氧原子或硫原子；n 为 2 至 6 的整数]具有极佳的单胺氧化酶抑制活性，可用作治疗剂或预防剂，防治抑郁症等神经疾病。
• Tomita,K. et al., Chemical and pharmaceutical bulletin, 1979, vol. 27, p. 2415 - 2423
  作者：Tomita,K. et al.

  DOI：——

  日期：——